Association between side effects of oral anti-diabetic drugs and self- reported mental health and quality of life among patients with type 2 diabetes
摘要
目的 探讨口服降糖药常见不良反应低血糖和体重增加对2型糖尿病患者心理建康和生存质量的影响.方法 全国16家三甲医院于2007年1至6月对486例2型糖尿病患者采用统一的患者问卷(AP RECAP-DM研究)进行病史采集,以低血糖担忧勘测量表(HFS-Ⅱ)测量患者治疗后对低血糖的担忧状况,欧洲生存质量五维量表(EQ-5D)测量患者治疗后的健康相关生存质量.结果 203例(41.8%)发生低血糖,其中18例(8.8%)为严重或极严重低血糖.93例(19.2%)有体重增加,其中11例(11.7%)体重增加超过5 kg.发生低血糖组HFS-Ⅱ分值高于无低血糖组[7.00(2.00~19.00)比0.00(0.00~7.00),P<0.01]而EQ-5D健康指数低于未发生低血糖组(0.90±0.12比0.93±0.13,P=0.003),其中严重或极严重低血糖组HFS-Ⅱ分值高于轻度低血糖组[20.00(8.00~30.00)比5.00(0.00~14.00),P<0.01].回归分析显示,HFS-Ⅱ分值与低血糖反应呈正相关(β=5.78,P<0.01),EQ-5D健康指数与低血糖反应呈负相关(β=-0.04,P<0.05),其中相对于轻度低血糖,严重低血糖或极严重低血糖组的HFS-Ⅱ分值较高(β=10.92,P<0.01).结论 在口服降糖药治疗过程中存在着较高的低血糖发生风险,与自我感觉不良和负性心理健康相关,有可能影响糖尿病远期预后.
Objective To examine the association between the side effects of oral anti-diabetic drugs (OAD) and self-reported mental health and quality of life among patients with type 2 diabetes mellitus (T2DM). Methods An observational, cross-sectional multicenter study with a retrospective medical chart review was conducted at 16 medical centers from around China. The T2DM patients were followed-up and treated with OAD alone prior to the index visit from January to September 2007. All subjects were ≥30 years old at the time of T2DM diagnosis and had received monotherapy or combination therapy of OAD for at least 6 months. Health-related quality of life was measured by the EuroQol-5D (EQ-5D) and Hypoglycemia Fear Survey (HFS) - Ⅱ. Results The symptoms of hypoglycemia were reported by 41.8% ( n = 203 ) of participants, and 19. 2% ( n = 93 ) experienced weight gain. For those reporting hypoglycemia, the scores were higher for HFS-Ⅱ [7.00(2.00 - 19.00)vs 0.00(0.00 -7.00), P <0.01] and lower for EQ-5D (0. 90 ± 0. 12 vs 0. 93 ± 0. 13, P = 0. 003 ) than those without hypoglycemic symptoms. According to the multivariate linear regression analysis, the symptoms of hypoglycemia were positively correlated with HFS- Ⅱ (β =5.78, P <0. 01 ) and negatively with EQ-5D (β = -0. 04, P <0. 05 ) after adjusting for patient and disease characteristics. Conclusion There is a high possibility of hypoglycemic risks among T2DM patients on OAD therapy. The self-reported hypoglycemia is associated with health-related quality of life and hypoglycemic fear. They may have an impact on the long-term prognosis.